With Ozempic Listing in Limbo, Novo Japan Chief Says Single-Dose Device Launch Unlikely This Year

Novo Nordisk Japan President Ole Moelskov Bech Ole Moelskov Bech, Japan president of Danish diabetes powerhouse Novo Nordisk, said on April 16 that this year’s launch is unlikely for new single-dose devices of its once-weekly GLP-1 agent Ozempic (semaglutide), which...read more